September 30, 2018 – Patient Worthy

qimono / Pixabay

The FDA Has Awarded Orphan Drug Designation to a Therapy for Complications After Haematopoietic Cell Transplantation

Post author:Anna Hewitt
Post published:September 30, 2018
Post category:Rare Disease

The United States Food and Drug Administration has awarded Orphan Drug Designation to an experimental PLX cell therapy (called PLX-R18) as a treatment for graft failure and incomplete haematopoietic recovery…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More